Perilipin-1 (PLN1), prostate cancer gene expression marker 1 (PCGEM1), myosin light chain 1 (MYL1), myosin heavy chain 7 (MYH7), myosin light chain 2(MYL2), olfactomedin 4 (OLFM4), lactotransferrin (LTF), phosphatidylinositol 3 (PI3), and recombinant keratin 17 (KRT17) were highly expressed in the SLPI high-expression group, which was significantly enriched in pathways associated with hypoxia, coagulation, allograft rejection, and late estrogen response (Figs. 3E–3F). The gene discussed is MYL2; the disease is cancer.